
04 Aug 2022
Hikma Pharmaceuticals: H1 results resilient, Generics pressure remains
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals: H1 results resilient, Generics pressure remains
Hikma Pharmaceuticals Plc (HIK:LON) | 1,599 -111.9 (-0.4%) | Mkt Cap: 3,548m
- Published:
04 Aug 2022 -
Author:
Stefan Hamill | Paul Cuddon | Kane Slutzkin -
Pages:
4 -